PCRX Pacira BioSciences, Inc.
Healthcare$24.36+4.33%ClosedMarket Cap: $958.2M
As of 2026-05-26
Valuation
P/E (TTM)
137.80
PEG
1.29
P/B
1.44
P/S
1.25
EV/EBITDA
10.01
DCF Value
$286.90
FCF Yield
14.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.3%
Operating Margin
3.1%
Net Margin
0.7%
ROE
0.7%
ROA
0.4%
ROIC
0.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $177.4M | 79.5% | $4.6M | $2.9M | $— | — |
| Q4 null | $196.9M | 79.5% | $3.2M | $1.6M | $— | — |
| FY null | $726.4M | 79.4% | $33.3M | $7.0M | $— | — |
| Q3 null | $179.5M | 80.9% | $6.4M | $5.4M | $— | — |
| Q2 null | $181.1M | 77.4% | $8.5M | $-4.8M | $— | — |
| Q1 null | $168.9M | 79.7% | $2.0M | $4.8M | $— | — |
| Q4 null | $187.3M | 78.7% | $24.7M | $16.0M | $— | — |
| FY null | $701.0M | 75.7% | $-73.4M | $-99.6M | $— | — |
| Q3 null | $168.6M | 76.9% | $-139.5M | $-143.5M | $— | — |
| Q2 null | $178.0M | 75.1% | $28.2M | $18.9M | $— | — |
| Q1 null | $167.1M | 71.6% | $13.2M | $9.0M | $— | — |
| Q4 2023 | $181.2M | 73.7% | $33.2M | $24.9M | $0.48 | — |